

# Microbiology and Infection Transmission:

microbiology, pathways of infection transmission in  
hospitals, established and emerging pathogens

HumanIC CBT1


26<sup>th</sup> Feb 2025

Dr Waseem Hiwar


# Dr Waseem Hiwar




M.Sc. Microbiology




Hiwar et al. (2021), *Indoor Air*, 31(5), 1308-1322.



Hiwar et al. (2022), *Indoor Air*, 32(11), e13161.



Hiwar et al. (2025), *COBEE 2025, Eindhoven*.



Eadie et al. (2022), *Scientific Reports*, 12(1), 4373.  
Hiwar et al. (2025), *Building and Environment*, 112734.



The PROTECT COVID-19 National Core Study on Transmission and Environment



Transport Risk Assessment for COVID Knowledge" (TRACK)



# Session Objectives



- To understand the role of **microbiology** in hospital environments.
- To identify key pathways of **pathogen transmission** in healthcare settings.
- To explore **established and emerging pathogens** in hospitals.
- To examine **infection control strategies**



# Obj.1/Type of Microorganisms

**Bacteria** are single-celled prokaryotic microorganisms found in all environments. Bacteria come in various shapes, including cocci (spherical), bacilli (rod-shaped), and spirilla (spiral-shaped), typically ranging from **0.1 to 10 µm** in size.

| Bacterial Group        | Main Pathogen                                            | Primary Infections                                              | Common Sources in Hospitals                                           |
|------------------------|----------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------------|
| Gram-Positive Bacteria | <i>Staphylococcus aureus</i> (MRSA)                      | Bloodstream infections, pneumonia, surgical site infections     | <b>Contaminated hands</b> , medical devices, catheters                |
|                        | <i>Clostridioides difficile</i>                          | Severe diarrhea, colitis                                        | <b>Contaminated hospital surfaces</b> , fecal-oral transmission       |
|                        | <i>Enterococcus spp.</i> (VRE)                           | UTIs, bloodstream infections, endocarditis                      | Catheters, <b>contaminated surfaces</b> , healthcare workers' hands   |
| Gram-Negative Bacteria | <i>Escherichia coli</i> (ESBL-producing <i>E. coli</i> ) | UTIs, bloodstream infections, sepsis                            | Urinary catheters, <b>poor hygiene</b>                                |
|                        | <i>Klebsiella pneumoniae</i> (CRE)                       | Pneumonia, bloodstream infections, UTIs                         | Hospital water sources, IV catheters                                  |
|                        | <i>Pseudomonas aeruginosa</i>                            | Ventilator-associated pneumonia (VAP), wound infections, sepsis | Biofilms in medical equipment, humidifiers, water systems             |
| Mycobacteria           | <i>Mycobacterium tuberculosis</i> (TB)                   | Pulmonary TB, disseminated TB                                   | <b>Airborne droplets</b> , infected patients, <b>poor ventilation</b> |



# Type of Microorganisms



**Fungi** are eukaryotic organisms and exist in diverse environments. While most fungi are harmless or beneficial, a few cause human diseases, particularly skin infections. They typically range in size from **2 to 10 µm** and reproduce through spores or budding.

| Fungal Group                          | Main Pathogen                  | Major Disease                                 | High-Risk Patients                                        | Common Sources in Hospitals                                                            |
|---------------------------------------|--------------------------------|-----------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------------------------------------|
| Moulds<br>(Multicellular Filamentous) | <i>Aspergillus spp.</i>        | Pulmonary/Invasive Aspergillosis              | Immunocompromised (Cancer, HIV, Transplant)               | Ventilation systems, damp walls, <b>air ducts</b>                                      |
| Macroscopic Filamentous Fungi         | <i>Mucorales (Zygomycetes)</i> | Mucormycosis (sinuses, lungs, skin)           | Diabetics, transplant recipients, ICU patients            | Dust, <b>humid hospital areas</b>                                                      |
| Yeasts (Single-Celled)                | <i>Candida spp.</i>            | Candidemia, Thrush, UTI, Invasive Candidiasis | ICU patients, catheter users, antibiotic-treated patients | IV catheters, urinary catheters, <b>ventilators</b> , healthcare workers' <b>hands</b> |





# Type of Microorganisms



**Viruses** require a host cell to replicate. They consist of genetic material (DNA or RNA) enclosed in a protein coat (capsid), sometimes with a lipid envelope. They are much smaller than bacteria, typically ranging from **5 to 300 µm** in size.

| Viral Group | Main Pathogen                       | Primary Infections                                               | Common Sources in Hospitals                                               |
|-------------|-------------------------------------|------------------------------------------------------------------|---------------------------------------------------------------------------|
| RNA Viruses | Influenza virus                     | Respiratory infections, pneumonia                                | Airborne droplets, contaminated surfaces, close contact                   |
|             | SARS-CoV-2 (COVID-19)               | Severe respiratory illness, pneumonia, multi-organ complications | <b>Airborne droplets</b> , close contact, contaminated surfaces           |
|             | Norovirus                           | Gastroenteritis, severe diarrhea                                 | Contaminated food, surfaces, person-to-person                             |
| DNA Viruses | Herpes simplex virus (HSV-1, HSV-2) | Neonatal herpes, encephalitis                                    | Direct contact, contaminated medical equipment                            |
|             | Hepatitis B Virus (HBV)             | Chronic liver disease, hepatocellular carcinoma                  | Bloodborne transmission, needlestick injuries, contaminated medical tools |



# Obj. 2/Pathogen Transmission Routes



| Mode of Transmission              | Typical Distance from Source | Route of Transfer to Another Human                | Respiratory Tract Entry Mechanism           | Respiratory Tract Entry Portal   |                                                                                       |
|-----------------------------------|------------------------------|---------------------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------|
| Airborne Transmission /Inhalation | Any distance                 | Through the air (suspended or moving via airflow) | Inhalation                                  | Anywhere along respiratory tract |    |
| Direct Deposition                 | Short                        | Through the air (semi-ballistic trajectory)       | Deposition on mucosa                        | Mouth, nose, or eyes             |    |
| Direct Contact                    | Short                        | Not through the air                               | Direct transfer (via touch)                 | Mouth, nose, or eyes             |   |
| Indirect Contact                  | Any distance                 | Not through the air (via intermediate object)     | Indirect transfer (via contaminated object) | Mouth, nose, or eyes             |  |




# Infection Transmission Routes



| Mode of Transmission             | Typical Distance | Route of Transfer                                                           | Entry Mechanism                                   | Entry Portal                     | Common Examples                                                |
|----------------------------------|------------------|-----------------------------------------------------------------------------|---------------------------------------------------|----------------------------------|----------------------------------------------------------------|
| Airborne Transmission/Inhalation | Any distance     | Through the air (suspended in aerosols or moving via airflow)               | Inhalation                                        | Anywhere along respiratory tract | Tuberculosis, Measles, COVID-19 (Airborne route)               |
| Droplet Transmission             | Short            | Through the air (large droplets expelled by coughing, sneezing, or talking) | Deposition on mucosa                              | Mouth, nose, or eyes             | Influenza, Pertussis, COVID-19 (Droplet route)                 |
| Direct Contact                   | Short            | Not through the air, direct skin-to-skin or mucosal contact                 | Direct transfer (via touch)                       | Mouth, nose, or skin             | MRSA, Scabies, Clostridioides difficile (hand-to-hand contact) |
| Indirect Contact                 | Any distance     | Not through the air, but via contaminated surfaces or objects               | Indirect transfer (via contaminated object)       | Mouth, nose, or eyes             | Fomites, Contaminated medical devices, Norovirus outbreaks     |
| Fecal-Oral Transmission          | Variable         | Ingestion of contaminated food, water, or hands touching infected feces     | Ingestion                                         | Gastrointestinal tract           | Hepatitis A, Cholera, Rotavirus, Giardia                       |
| Vector-Borne Transmission        | Variable         | Via insect or animal bite from infected vectors (mosquitoes, ticks)         | Vector-mediated inoculation (bite or penetration) | Skin, bloodstream                | Malaria, Dengue, Lyme disease, West Nile virus                 |



Fig 4. WHO Bacterial Priority Pathogens List, 2024



Funded by  
the European Union



# Summary of Epidemiological Information on Proposed Priority Pathogens

| Family           | Pathogen                                      | Vector/Reservoir                                 | Mode of Transmission                                           | ent of Person-to-Person Transmis | Spread                                                       |
|------------------|-----------------------------------------------|--------------------------------------------------|----------------------------------------------------------------|----------------------------------|--------------------------------------------------------------|
| Arenaviridae     | Mammarenavirus lassaense                      | Mastomys rodents                                 | Contact with infected rodents, person-to-person                | Sufficient to cause outbreaks    | Africa                                                       |
| Bacteria         | Vibrio Cholerae (sero 01)                     | Aquatic environment, human hosts                 | Fecal-oral transmission, contaminated water sources            | Some                             | South Asia                                                   |
| Bacteria         | Klebsiella Pneumoniae                         | Humans, environmental reservoirs                 | Nosocomial transmission, person-to-person spread               | Some                             | Reported worldwide                                           |
| Bacteria         | Yersinia Pestis (Plague)                      | Rodents, fleas                                   | Flea-borne transmission, person-to-person spread               | Some                             | Asia, Africa, Americas                                       |
| Bacteria         | Shigella Dysenteriae 1                        | Humans                                           | Fecal-oral transmission, contaminated food/water               | Sufficient to cause outbreaks    | Primarily in developing countries, potential for global spre |
| Bacteria         | Salmonella Enterica (various non-typhoidal)   | Animals, environment, humans                     | Food-borne transmission, person-to-person spread               | Sufficient to cause outbreaks    | Reported worldwide                                           |
| Hantaviridae     | Orthohantavirus Sin Nombre                    | Deer mice                                        | Inhalation of virus from rodent excreta                        | Little or none                   | Primarily confined to endemic regions in Asia                |
| Hantaviridae     | Orthohantavirus Seoul                         | Rats                                             | Inhalation of virus from rodent excreta                        | Little or none                   | Primarily confined to North America                          |
| Hantaviridae     | Orthohantavirus Dobrava                       | Ticks, rodents                                   | Tick-borne transmission, contact with infected animals         | Some                             | Primarily confined to endemic regions in Asia, Europe        |
| Phenuiviridae    | Bandavirus dabieense                          | Ticks, small mammals                             | Tick-borne transmission, contact with infected rodents         | Some                             | Outbreaks in parts of Asia                                   |
| Coronaviridae    | Sub genus Sarbecovirus                        | Bats, humans                                     | Respiratory transmission                                       | Sufficient to cause outbreaks    | Global, already caused a PHEIC                               |
| Coronaviridae    | Sub genus Sarbecovirus                        | Bats, humans                                     | Respiratory transmission                                       | Sufficient to cause outbreaks    | Global                                                       |
| Flaviviridae     | Orthoflavivirus usutuivrus                    | Mosquitoes                                       | Mosquito-borne transmission                                    | Little or none                   | In parts of Africa and South America                         |
| Filoviridae      | Orthomaburgvirus marburgense                  | Fruit bats, potential animal reservoir           | Contact with infected bodily fluids                            | Sufficient to cause outbreaks    | Primarily in Central and East Africa                         |
| Filoviridae      | Orthobolavirus zaireense                      | Fruit bats, potential animal reservoir           | Contact with infected bodily fluids                            | Sufficient to cause outbreaks    | Primarily in Central and East Africa                         |
| Flaviviridae     | Orthoflavivirus flavivirus                    | Mosquitoes, non-human primates                   | Mosquito-borne transmission                                    | Little or none                   | Widespread in tropical and subtropical regions               |
| Flaviviridae     | Orthoflavivirus dengue1                       | Mosquitoes                                       | Mosquito-borne transmission                                    | Little or none                   | Outbreaks in the Americas, Africa, Asia, and the Pacific     |
| Flaviviridae     | Orthoflavivirus zikaense                      | Aedes mosquitoes                                 | Mosquito-borne, potential for vertical and sexual transmission | Some                             | Outbreaks in parts of Asia, Africa, Europe                   |
| Orthomyxoviridae | Alphainfluenzavirus influenza H5, H7, H9, H10 | Avian reservoirs, humans                         | Respiratory transmission, potential for zoonotic               | Little or none                   | Outbreaks in parts of Asia and Europe                        |
| Orthomyxoviridae | Alphainfluenzavirus influenza H5, H7, H9, H10 | Avian reservoirs, humans                         | Respiratory transmission, potential for zoonotic               | Little or none                   | Worldwide distribution                                       |
| Orthomyxoviridae | Alphainfluenzavirus influenza H1, H3          | Respiratory transmission, potential for zoonotic | Respiratory transmission                                       | Sufficient to cause outbreaks    | Outbreaks in parts of Asia                                   |
| Orthomyxoviridae | Henipavirus Nipah                             | Bats, humans                                     | Bat-borne transmission, person-to-person spread                | Sufficient to cause outbreaks    | Primarily confined to Afghanistan and Pakistan               |
| Paramyxoviridae  | Enterovirus poliovirus                        | Humans                                           | Fecal-oral transmission, contaminated food and water           | Sufficient to cause outbreaks    | Historically widespread, now confined to laboratories        |
| Picornaviridae   | Orthopoxvirus Variola                         | Humans                                           | Contact with infected individuals                              | Sufficient to cause outbreaks    | Endemic in Central and West Africa, already caused a PHE     |
| Poxviridae       | Lentivirus human6                             | Endemic in humans                                | Sexual transmission, endemic in humans                         | Endemic in humans                | Global                                                       |
| Retroviridae     | Alphavirus equine encephalitis                | Mosquitoes, rodents                              | Mosquito-borne transmission                                    | Little or none                   | Outbreaks in Asia, Africa, and the Americas                  |
| Togaviridae      | Alphavirus Venezuelan                         | Mosquitoes, rodents                              | Mosquito-borne transmission                                    | Little or none                   | Outbreaks in Central and South America                       |





# Exercise 1:

## Most Effective Infection Control Strategy

G1 - Ventilation

G2 - UV disinfection

G3 - HEPA filters

- Each group must argue why their assigned strategy is the most effective (10 minutes).
- Other groups can challenge their claims (10 minutes).




Funded by  
the European Union

# infection control strategies



How to minimise the transmission of airborne pathogens?




Funded by  
the European Union

# Ventilation



- Ventilation is the process of introducing and circulating clean air into indoor spaces to dilute and displace polluted air, using mechanical and natural ventilation.



**Figure 1:** Airborne pathogen mitigations

Morawska, Lidia, et al. "How can airborne transmission of COVID-19 indoors be minimised?." *Environment international* 142 (2020).



Funded by  
the European Union



# Type of Ventilation

## **Natural ventilation:**

Operable windows, vents, and other openings to allow air exchange driven by natural wind and temperature differences.

## **Mechanical ventilation:**

Like Heating, Ventilation and Air Conditioning (HVAC) to control indoor air quality by regulating airflow rates and filtration.

## **Hybrid systems:**

Combines elements of both natural and mechanical systems to optimize energy efficiency while maintaining air quality.




Funded by  
the European Union




## The impact of ventilation rate on reducing the microorganisms load in the air and on surfaces in a room-sized chamber

Waseem Hiwar<sup>1</sup> | Marco-Felipe King<sup>1</sup> | Harith Kharrufa<sup>2</sup> | Emma Tidswell<sup>1</sup> | Louise A. Fletcher<sup>1</sup> | Catherine J. Noakes<sup>1</sup>



**FIGURE 8:** Airborne bioaerosol load under steady-state conditions at 3 and 6 ACH ventilation rates and at two locations (ventilation supply and extract) in the chamber.




**FIGURE 9:** The mean deposited microorganisms load under the steady state conditions at 3 and 6 ACH ventilation rates sampled near the ventilation inlet and the outlet.



# Ultraviolet Disinfection



Electromagnetic radiation having a wavelength between 100 and 400 nm



Further subdivided into 4 segments, vacuum UV, short-wave UV (UV-C), middle-wave UV (UV-B) and long-wave UV (UV-A)

[https://2008.igem.org/Team:Bologna/UV\\_radiation/](https://2008.igem.org/Team:Bologna/UV_radiation/)




Funded by  
the European Union

# Ultraviolet Disinfection



UV-A and UV-B activate the melanocytes in the skin to produce melanin



UV-B radiation also causes sunburn




Funded by  
the European Union

# Ultraviolet Disinfection



UV-C radiation (254nm) is absorbed by the DNA and is the most likely of the three to cause skin cancer



<https://www.flowtechinc.com/uv-c-germicidal-technologies-effectiveness-against-covid-19/>



Funded by  
the European Union

# History of UVGI



1930's and 40's - UV lamps used extensively in Tuberculosis (TB) wards in the USA

Numerous anecdotal accounts of the benefits of UVGI in these wards

Wells et al – Harvard University – 4 year study – UV in schools - reduced the spread of measles and chickenpox and mumps

Riley – carried on the work – looking at the control of TB

Since Riley's work there had been little work done on UV

- Reduction in TB cases due to improved drug therapies
- Difficulty in demonstrating a real health effect
- Concerns over the safety of UVGI



## **Renewed Interest in Ultraviolet disinfection**

- Increased incidence of TB
- Recognition that existing engineering controls have serious deficiencies

### **As a result:**

- Ultraviolet germicidal irradiation is now a recognised method for inactivating a wide range of biological agents


The efficacy will depend upon a range of locational and operational factors

- UV Light intensity
- Susceptibility of microorganism
- Passage of air through UV field


# UV Disinfection Strategies




## Stand-alone devices




## In-duct systems



## Upper Room



# Susceptibility of microorganism



—◆— *Serratia marcescens*      —■— *Bacillus subtilis* spores      —▲— *Burkholderia cepacia*



# scientific reports




OPEN

## Far-UVC (222 nm) efficiently inactivates an airborne pathogen in a room-sized chamber

Ewan Eadie<sup>1✉</sup>, Waseem Hiwar<sup>2</sup>, Louise Fletcher<sup>2</sup>, Emma Tidswell<sup>2</sup>, Paul O'Mahoney<sup>1,3</sup>, Manuela Buonanno<sup>4</sup>, David Welch<sup>4</sup>, Catherine S. Adamson<sup>5</sup>, David J. Brenner<sup>4</sup>, Catherine Noakes<sup>2</sup> & Kenneth Wood<sup>6</sup>




- 100-280 nm (UV-C radiation)
- 250-280 nm (UVGI) at germicidal doses is potentially hazardous, biophysical
- 200-230 nm Far UV-C radiation




**Figure 2: Far UV-C wavelength**

- Nucleic acids and proteins absorb photons, making wavelengths below 230 nm efficient for deactivation.
- Airborne viral infections are commonly bound in aerosol droplets, which have high protein absorption.




<https://phys.org/news/2021-10-specific-uv-wavelength-low-cost-safe.html>



<https://www.wsws.org/en/articles/2023/01/14/veda-j14.html>

- Far-UV - typically in the wavelength range from **200 to 230 nm**
- Krypton Chloride (KrCl) excimer lamps with a primary emission wavelength of **222 nm**, and low residual emission throughout the ultraviolet region of the electromagnetic spectrum
- Have been shown in **laboratory experiments to inactivate** gram-positive and gram-negative bacteria, drug-resistant bacteria, influenza viruses and human coronaviruses including the SARS-CoV-2 virus
- Far-UVC excimer lamps are much less likely than conventional (254 nm) germicidal UV sources to **induce acute adverse reactions on skin and eyes**, and studies to date in animal and human models have not demonstrated any long-term adverse health effects



# HEPA filter unit





Figure 1 The performance of the air cleaning device at different fan speeds with bioaerosols of *A. fumigatus* – the blue lines represents the raw data from the ten replicate samples and the red lines are the mean concentrations over the ten replicate samples.



# Building and Environment

Volume 274, 15 April 2025, 112734



## Experimental analysis to quantify inactivation of microorganisms by Far-UVC irradiation in indoor environments.

Waseem Hiwar<sup>a</sup>  , Catherine S Adamson<sup>b</sup>, David J Brenner<sup>c</sup>,  
Louise A Fletcher<sup>a</sup>, Marco-Felipe King<sup>a</sup>, James B. McQuaid<sup>d</sup>, Emma Tidswell<sup>a</sup>,  
Catherine J Noakes<sup>a</sup>, Kenneth Wood<sup>e</sup>, Ewan Eadie<sup>f</sup>




Funded by  
the European Union




## Exercise 1:

The data was obtained from controlled experiments carried out in the Leeds test chamber using *Staphylococcus aureus* over 4 days. For each experiment ten replicate samples were taken with the device switched off (control samples) and with the device switched on (test samples) and all the data is in cfu/m<sup>3</sup>. There was no sampling for the first hour, then, 10 samples were taken when the device is off, 10 samples when the device is on (at a ventilation rate of 1.5, 3, 6 and 9 ACH).







# Reactive Air Purification Technology




- Negative Air Ionisation




Ionisers in use in a UK Hospital



Funded by  
the European Union



Effect of negative ions on the airborne concentration of *Staphylococcus aureus*



Effect of negative ions on the airborne concentration of *Bacillus subtilis* spores

# Reactive Air Purification Technology



- Ozone
  - An allotrope of oxygen with **three oxygen atoms**
  - **Unstable** because the gas will readily degrade back to its stable state, diatomic oxygen
  - In air it has a **pungent odour** that is noticeable to most persons at levels above 100 ppb
  - Because it is a strong oxidant, extended exposure to ozone containing air is **harmful** (hazardous pollutant)
  - Can be generated by **photochemical, electrolytic** and **radiochemical methods**
  - Ozone is known to have **antibacterial activity**
  - Background levels are usually around **20 – 30 ppb**



# Reactive Air Purification Technology



- Hydroxyl Radicals

Discovered through work looking at the natural disinfection capacity of the open air – The Open-Air Factor



Patients with TB were often treated using ‘fresh air and sunshine’




Funded by  
the European Union

# Evaluating the efficacy of air treatment devices

## Controlled Environment Testing


### Steady state test

- Room is subject to a continuous source of contamination
- Replicate samples are taken with the device switched off and again with the device switched on
- The difference between the two data sets is the reduction due to the device



### Decay test

- Short term contamination event
- Samples are taken at set time intervals after contamination ceases with no device operating
- Test is repeated with the device switched on
- The difference in decay rate with and without the device operating indicates the efficacy of the device



# Real Environment Testing



Testing devices in real environments has **advantages** and **disadvantages**.

- It can be better to test in real environments such as hospitals etc. so you can investigate the influence of environmental conditions such as **temperature, relative humidity, ventilation rate** and the **concentration of microorganisms** which will vary over time.
- It also allows you to look at other factors such as the ‘usability’ of the device.
  - Does the device produce too much **noise**?
  - Does the device create a **draft**?
  - Does the device create a **smell**?
  - Do the device **get in the way**?
- If you are evaluating the performance of a device intended to be used in a hospital, by doing a full clinical trial you can also determine if the device produces a **reduction in infections** rather than just a **reduction in the level of contamination**.
- The **big disadvantage** to real environment trials is **the cost** and also the fact that they are **uncontrolled** so it can be difficult to explain differences in performance fi comparing different devices.